ETH zürich

Mapping human cell phenotypes to genotypes with single-cell genomics

Review Article

Author(s): Camp, J. Gray; Platt, Randall; <u>Treutlein, Barbara</u>

Publication date: 2019-09-27

Permanent link: https://doi.org/10.3929/ethz-b-000368526

Rights / license: In Copyright - Non-Commercial Use Permitted

Originally published in: Science 365(6460), https://doi.org/10.1126/science.aax6648

Funding acknowledgement: 758877 - Reconstructing human cortex development and malformation with single-cell transcriptomics (EC)

1	Mapping human cell phenotypes to genotypes with single-cell genomics		
2			
3 4	J. Gray Camp ¹ , Randall Platt ² , Barbara Treutlein ²		
4 5	J. Gray Camp, Randair Flatt, Darbara Heutien		
6	Affiliations:		
7	¹ Institute of Molecular and Clinical Ophthalmology Basel, Basel, Switzerland		
8	² Department of Biosystems Science and Engineering, ETH Zürich, Basel, Switzerland		
9			
10	ABSTRACT		
11 12	The cumulative activity of all of our cells, with their myriad of interactions, life histories, and		
12	environmental experiences, gives rise to a condition that is uniquely human, and specific to		
14	each individual. It is an enduring goal to catalog our human cell types, to understand how they		
15	develop, how they vary between individuals, and how they fail in disease. Single-cell genomics		
16	has revolutionized this endeavor as sequencing-based methods provide a means to		
17	quantitatively annotate cell states based on high-information content and high-throughput		
18	measurements. Together with advances in stem cell biology and gene editing, we are in the		
19	midst of a fascinating journey to understand the cellular phenotypes that compose human		
20	bodies and how the human genome is used to build and maintain each cell. Here we will review		
21	recent advances into how single-cell genomics is being used to develop personalized		
22	phenotyping strategies that cross subcellular, cellular, and tissue scales to link our genome to		
23 24	our cumulative cellular phenotypes.		
25	Phenotyping in the single-cell sequencing era		
26			
27	Phenotype can mean many things, but in general it is a way to classify a set of properties that		
28	arise from the interaction of an individual's genotype with its environment. It is a reductionist, yet		
29	powerful, approach to take human phenotyping down to the level of single cells and use		
30	molecular states within cells to establish phenotypes at the molecular, cellular, and		
31 32	tissue/system level. Single-cell sequencing technologies can measure thousands of individual features per cell for thousands of cells at a time, providing a quantitative and ultra-high		
32 33	resolution snapshot of cell and molecular states composing a human tissue, organ, or other		
34	biosystem. Currently, there are protocols available to measure the RNA content, DNA sequence		
35	and methylation status, chromatin structure and accessibility, and protein composition in single		
36	cells(1). In addition to molecular features, cell histories can be measured in certain scenarios		
37	where mutations have arisen in nuclear(2-4) or mitochondrial(5) DNA that distinguish lineages.		
38	Furthermore, in genetically tractable model systems (such as mice, zebrafish, and organoids), it		
39	is possible to record cell fate histories and infer lineage trees using reporter barcodes and		
40	genetic scarring based on RNA-guided CRISPR (clustered regularly interspaced short		
41	palindromic repeats)-associated (Cas) nucleases(6-9). So far, generally one or two single-cell		
42 43	measures have been used to phenotype individual cells within tissues in each experiment. However, the field is moving towards multimodal measurements from the same cell that capture		

transcriptomic, genomic, epigenomic, and lineage states to enhance feature quantifications and
give a richer picture of a cell's phenotype at any given moment(*10-12*). These technologies are

46 forcing scientists to grapple with previous notions of "cell type", as cell properties can vary

47 discretely (type or subtype), as well as continuously (state), and classification may not always

follow rigid hierarchies(13). An additional layer of complexity arises in developing systems
 where cell states and tissue morphologies are changing rapidly with time. Single-cell

- where cell states and tissue morphologies are changing rapidly with time. Single-cell
 sequencing captures transient states, and computational approaches enable trajectory(*14*) and
- 51 lineage(9) reconstructions.

52 The microenvironment of each cell can also be critical to a individual cell's phenotype. 53 Spatial transcriptomic and proteomic approaches based on multiplexed RNA hybridizations(15, 54 16) or protein immunohistochemistry(17), in situ sequencing(18-20), mass cytometry(21) or 55 other strategies(22) can be used to measure cell types and states in situ. In addition, methods 56 are being developed to analyze spatial locations of molecules within a cell and cells within a 57 tissue using barcoded oligonucleotides that can couple together when the molecules are close 58 enough to physically interact(23, 24). These pairwise interactions are encoded in DNA and can 59 be measured by high-throughput sequencing, and computational analyses enable spatial 60 reconstruction of cell interactions based on the molecular proximities.

61 Single-cell phenotyping has provided extraordinary atlases of model organisms that 62 span organ systems from the same animal(25-27), link cell morphologies with molecular 63 features(28), resolve cell type classifications(18, 29) and gradients of cell states (30, 31) 64 spatially, and assemble cell fates maps using lineage recording(7). This wave is extending to 65 developing, mature, and aged human organs(32, 33), identifying previously undocumented 66 human cell types(34-36) and providing a quantitative framework to classify human cell subtypes 67 and other states (37, 38). A major technical goal is to integrate (39, 40) all possible feature 68 detection methods (RNA, DNA, chromatin state, lineage, etc.) performed independently or in 69 combination in single cells, and render these measurements into three-dimensional spatial 70 volumes with subcellular and temporal resolution (Figure 1). By measuring cell heterogeneity 71 with such high information content techniques, emergent phenotypes at the tissue or biosystem 72 level (system phenotype) such as composition, regulatory states, cell interactions, spatial 73 constructions, and differentiation trajectories can be compared across environmental and 74 genetic conditions. Because human development is not deterministic, it will be interesting to see 75 how variable organ reconstructions are across different humans. Similar to the Human Genome 76 Project, the Human Cell Atlas (HCA) consortium will confront the challenge of how to generate a 77 reference organ map when the organ may look different in every person. The process of 78 assessing such variations using integrated multi-modal measurements, as is being proposed in 79 HCA projects over the next few years, will help to create common coordinated frameworks for 80 sampling tissues, processing samples and data, and computational comparisons between 81 methods and individuals.

82

83 Disease associated cell phenotypes

84

As each human and mouse organ is mapped at single-cell resolution across space and
time, a next phase of inquiry is to understand how genetic changes impact human phenotypes.
Disease association studies have used naturally occuring mutations to identify disease-causing

88 genes: these genes are Mendelian, have strong-effect coding mutations, or have been 89 experimentally validated. Disease-causing genes can be mapped to cell types by identifying the 90 cell population where the gene is expressed (multi-organ(41), kidney(42), cortex(43); Figure 2a). 91 A notable example was shown recently when researchers mapped out the cell types within the 92 adult human lung, and identified a new human cell type ("ionocyte"), which was the only type 93 that expressed CFTR at high levels and therefore likely mediates the lung pathology observed 94 in cystic fibrosis (35, 36). However, most disease associated mutations identified through 95 GWAS are likely regulatory, and the genes they regulate are currently unknown. Multimodel measures combining single-cell DNA. RNA, and chromatin can locate portions of the genome 96 97 that are active in a certain cell type or state providing a link from the regulatory genome to the 98 cell and even tissue phenotype. Future exploration into population measures of cell and tissue 99 phenotypes at the single-cell level(44, 45), similar to what has been done using bulk RNAseg of 100 adult human organs from the GTEx project(46), will be critical to identify the mechanism of 101 action of most GWAS variants.

102 In addition, researchers have started to phenotype human diseased tissues (Figure 2b), 103 thereby elucidating spatial glial neuron interactions in Amyotrophic Lateral Sclerosis(47), 104 identifying disease associated microglia in Alzheimers disease(48) and fibroblasts in Arthritis 105 (49), profiling pancreatic islets in health and type 2 diabetes (50), and identifying cellular rewiring 106 during colitis(51). These types of analyses promise to bring about a new phase of molecular 107 disease classification and diagnosis, and guide the development of therapies that can target the 108 specific cell types impacted by a given disease. This is already happening for various 109 cancers(52), however, there are major challenges requiring innovation to bring single-cell 110 sequencing technologies to patients with other disorders on a clinical scale. Protocols to 111 minimize cell loss during experiments could make it feasible to work with minute amounts of 112 input material (53). Apart from cancer, it is difficult to acquire tissue from most diseased 113 microenvironments in patients, and miniaturzied biopsies from healthy and diseased regions of 114 a tissue could open up disorders that lack clear molecular phenotypes. Industrialization of the 115 single-cell –omics pipeline from sample preparation and sequencing, to data analysis is also 116 required. This could include protocol optimizations to reduce cost of cell throughput while 117 retaining sensitivity (25, 54, 55), to increase sample multiplexing based on reference 118 polymorphisms (45) or tagging (56, 57), and to compress phenotyping by experimentally 119 enriching for diagnostic features or select against non-diagnostic features (58). In situ 120 sequencing approaches may be another route to increased throughput once methods have 121 been industrialized. Finally, robust software pipelines will be needed that can rapidly analyze the 122 high-dimensional data and output perturbation landscapes that are able to diagnose disease. 123 Comparing human with mouse and other species can reveal the power and limitations of 124 model organisms for understanding human genotype to phenotype relationships. In many 125 cases, the same broad cell classes are found in mammalian tissues, and cell states can be 126 integrated across species (39). For example, recent single-cell analysis of the mouse kidney 127 suggested that most known kidney disease-associated genes in humans map to the mouse cell 128 counterparts(59). However there are cases in which the human and mouse tissues have 129 diverged significantly in terms of cell composition and gene expression. For example, humans 130 and other primates have a specialized area of the retina called the fovea, which can be 131 distinguished based on the particular proportion and types of retinal neurons that have distinct

132 expression signatures from other areas of the retina(60). Mice on the other hand lack a fovea

altogether, making it a poor model system for many blindness disorders. It may be possible to

134 leverage such differences to understand the underlying genetic mechanisms that control human

135 cell phenotypes. Altogether, comparisons between species, between human individuals, and

- between healthy and disease conditions can illuminate variety of human cell phenotypes, and
 help to link the genome to specific cell states. Now we need creative strategies to move past
- help to link the genome to specific cell states. Now we need creative strategies to move past
 correlation and establish the functional relevance of the observations from these highly-resolved
- 139 maps.

140

141 Stem cell and genetic manipulation tools

142

143 There has been an exciting revolution in the stem cell biology field, which has made it possible 144 to generate diverse human cell types in controlled 2D cultures(61), and to generate complex 3D 145 tissues that resemble the primary tissue/organ counterparts (termed organoids)(62, 63). 146 Organoid protocols have been developed for various parts of the brain, liver, intestine, lung, 147 kidney, stomach, etc., and the protocols are being optimized for stereotyped morphology(64) 148 and inter-organoid reproducibility (65, 66). Many of these systems have been analyzed by 149 single-cell genomics and the data compared with their primary tissue counterparts to quantitate 150 how accurately cells states are recapitulated (67). The power of these in vitro systems is that 151 they are specific to an individual, enable replicate measurements over a time course, are 152 amenable to genetic manipulation and lineage recording in diverse environmental conditions, 153 could be used for high-throughput screening, and can recapitulate certain disease phenotypes 154 (Figure 3). For example, recent work showed that cerebral organoids recapitulate neuronal 155 migration defects observed in patients with periventricular nodular heterotopia, and single-cell 156 transcriptomics identified a perturbed differentiation trajectory (68). In addition, cerebral 157 organoids were used to identify specific cell states that were sensitive to hypoxia conditions that 158 occur in premature births, and organoids were used to screen for small molecules that 159 prevented loss of of these cell states(69). As detailed above, integrating multiple single-cell 160 genomic measurements together with cell history recorders and 3D spatial reconstructions will 161 soon provide very exciting high-resolution phenotyping strategies in these personalized models 162 of disease. 163 Culture systems that can recapitulate human development and physiology in vitro enable 164 researchers to use RNA-guided CRISPR-associated (Cas) nucleases to interrogate these 165 systems and link genotype to phenotype. CRISPR-Cas nucleases come in various natural as

166 well as synthetically engineered flavors enabling diverse genome and epigenome

167 modifications(70). These tools were originally established based on the Cas9 protein for gene

- 168 editing in immortalized mammalian cell lines(71-73) and then harnessed to link phenotype to
- 169 genotype using both a forward and reverse genetics approach (Figure 4). Reverse genetic
- approaches based on CRISPR, generally termed pooled CRISPR screens, involve the: i)
- production of genome-scale or sub-genomic gRNA libraries; ii) low multiplicity of infection
 delivery to cells such that single cells receive single perturbations; iii) enrichment or depletion of
- 173 cells based on a cellular phenotype of interest (e.g. proliferation, death, or presence/absence of
- selectable marker or reporter); and iv) identification and analysis of genes corresponding to
- 175 enriched and/or depleted gRNAs. Pooled CRISPR screens were originally demonstrated in

176 human cancer cell lines (74, 75) but were recently extended and optimized in human iPSC 177 culture systems to identify genes that regulate pluripotency(76). Moving beyond gene knockout, 178 catalytically inactivated Cas proteins fused to effector domains enable diverse perturbations. 179 including transcriptional activation (CRISPRa) or inhibition (CRISPRi)(77), DNA methylation or 180 demethylation(78), histone acetylation(79), DNA (80) or RNA(81) base editing, as well as 181 others(82). Many of these RNA-guided Cas effector proteins have successfully been used in 182 pooled CRISPR screens further expanding our capacity to link diverse genetic and epigenetic 183 features to phenotypes (77, 83-85). Researchers have started to bring these technologies to 184 human iPSC cells by establishing stable cell lines that have inducible expression of the different 185 Cas effectors, and these lines can then be used to explore phenotype-genotype relationships in 186 a diversity of human cellular and tissue contexts. (5, 86, 87)

187 More recently, exciting work has merged CRISPR screening with single-cell genomic 188 readouts(88-91). In these methods pools of gRNAs are introduced into cells along with a Cas 189 protein such that cells express different gRNAs. Transcriptomes can be sequenced in single-190 cells and the gRNA that is expressed per cell can be determined based on an associated 191 barcode, or through direct sequencing of the gRNA. In this way, the effect of many different 192 gene perturbations can be examined in the same experiment with single-cell resolution. There 193 are several considerations when designing single-cell perturbation screens in organoids, and 194 optimizations on the initial protocols to reduce barcode recombination will enable more sensitive 195 and accurate readouts (92). One needs to determine how many genes can be targeted based on 196 a power analysis taking into account cell heterogeneity of the system (# cells), proportion of 197 mutant and wild-type cells, depth of sequencing, # reads per cell, effect size of perturbation, and 198 cost. Clonal selection within a stem cell culture or within an organoid can have an impact on the 199 results, especially if the organoid system is initiated from a composite of many different stem 200 cell clones (e.g. cerebral organoids). Cas protein can be constitutively or transiently expressed, 201 or induced through multiple strategies (e.g. Tet/On, Cre) and gRNAs can be introduced into the 202 cells or organoid through different delivery methods (AAV, lentivirus, transposon). Currently the 203 gRNA or barcode needs to be the read-out rather than the genomic lesion making the readout 204 correlative. If the proportion of mutant cells is too high, then the organoid may not develop 205 properly and the presence of a sufficient proportion of wild type cells could buffer mutant effects. 206 It is important to incorporate a selection feature of the cells receiving the gRNA (e.g. 207 Fluorescence). Finally, genetic perturbations might be cell autonomous or non-autonomous and 208 this can be difficult to distinguish in pooled screens with mosaic organoids, making arrayed 209 screening important alternatives. CRISPR/Cas9 screening based on single-cell sequencing in 210 iPSC-derived organoids has a rich future in the exploration of human cell phenotype to 211 genotype relationships. This will be made possible through innovations to increase throughput 212 to perform combinatorial genetic interaction and massively multiplexed screens, new 213 technologies to combine screening with molecular recording (7, 93) and lineage tracing, and in situ readouts(94) based on in situ sequencing technologies to open up exploration into spatial 214 215 effects of genetic perturbation. 216


217 Conclusions and outlook: In this review, we aimed to provide a foundational overview of the 218 current state of single-cell genomic-based phenotyping of human organs and organoids, and 219 how CRISPR-Cas technologies will enable phenotypes to be functionally linked to regions of the 220 human genome. We envision that the descriptive phase of single-cell genomics, where cell 221 phenotypes are catalogued for each healthy human tissue, will culminate in 4D resolved in silico 222 simulations that enable researchers to walk into the tissue, point to a cell at a location within the 223 tissue at a particular time point, and know its molecular features and its interaction with other 224 cells within the microenvironment. In the short term, the goal is to integrate and render different 225 feature (RNA, DNA, chromatin state, lineage) measurements into three-dimensional spatial 226 volumes with subcellular and temporal resolution. It will be exciting to incorporate single-cell 227 molecular measurements with in toto imaging of developing or cleared human organs/organoids 228 with cellular and subcellular resolution (95-98). Innovations in virtual-reality microscopy are 229 starting to bring together immersive visualization and simulation of imaged-based data with 230 hand gesture control, and the first virtual reality platform for the visualisation and analysis of 231 single-cell gene expression data has been developed(99).

232 Perturbation screens in human cells could be integrated with 4D spatiotemporal models 233 to weigh the functional relevance of genes and regulatory regions for establishing molecular, 234 cellular and systems-level phenotypes. However, there are still many limitations that require 235 innovations in the stem cell and organoid field that will enhance the biological insight that can be 236 attained from these efforts. Specifically, organoid morphology may not be stereotyped, there are 237 missing or off-target lineages, organoids are not integrated with other relevant organ systems, 238 and iPSC-derived organoids follow development and may not reflect processes in adults. It will 239 be important to continue to use single-cell genomics to assess the precision of novel organoid 240 protocols, and compare lineage and fate maps with other mammalian counterparts. 241 Establishment of stem cell resources from different populations (100) or the same individuals 242 from whom there are reference atlases will be useful for establishing a foundation for 243 quantitative comparisons across protocols. Furthermore, well characterized iPSC lines that 244 contain various flavors of CRISPR/Cas systems for genetic purturbation screens and cell fate 245 recording, together with a suite of diverse fluorescent reporters(101), will push the field forward.

246 Finally, a drive toward industrialization of single-cell sequencing pipelines on diseased 247 tissues and organoid models could bring exciting prospects for disease classification and 248 personalized medicine. This will require close collaborations between basic and clinical 249 researchers, as well as industry partners, to identify the unmet medical needs where single-cell 250 sequencing could have the most immediate effect. There are many disorders where multiple 251 genetic drivers are known, however it is increasingly clear that the different causative genes are 252 expressed in very different cell types(102). This is a major conundrum where molecular 253 dissection of the dissorder in primary tissues and/or organoid models could enable a refined 254 classification of the disorder, and also identify mechanisms that underly particular disease 255 presentations. Optimization of organoid protocols together with increased single-cell genomic 256 throughput would also enable testing disease-associated environmental conditions and potential 257 pharmacological-, gene- and cell-based therapies. There are many obstacles that remain, 258 however the field is moving forward at an extraordinary pace and it will be exciting to see where 259 it goes from here.

- 260
- 261
- 262


263 **Figures** 264




265

266 Figure 1: Human phenotyping in the single-cell genomics era. (a) Many different single-cell

- 267 genomic methods have been developed to profile cell heterogeneity in human organs across
- space and time. (b-c) These measurements can be integrated to build phenotypic maps that
- cross sub-cellular, cellular, and tissue/system scales.



- 270
- 271
- 272 Figure 2: Human organ maps can resolve disease phenotypes. (a) Single-cell resolved
- 273 human organ phenotypic maps can be used to identify cell states that are likely most impacted
- by human disease. (b) In the future, diseases can be grouped into molecularly defined
- 275 subclasses based on single-cell genomic (SCG) phenotyping. Many obstacles remain for
- bringing SCG phenotyping directly to patients in a clinical setting.
- 277
- 278
- 279



280


Figure 3: Human organoids to recapitulate human phenotypes in vitro. (a) Human

organoids derived from induced pluripotent or adult stem cells are genetically tractable and can

283 recapitulate complex tissue level phenotypes in controlled culture environments.

284

285



286

Figure 4: Genetic manipulation toolkit to link phenotype to genotype using stem cells. A diverse array of genetic manipulation tools based on the CRISPR/Cas system can be deployed in organoids to test predictions from single-cell genomic surveys of organs and organoids and link genotype to phenotype. Shown are examples of potential CRISPR/Cas toolkit applications in human organoids.

- 292
- 293

294 References:

- 295
- 2961.X. Chen, S. A. Teichmann, K. B. Meyer, From Tissues to Cell Types and Back: Single-297Cell Gene Expression Analysis of Tissue Architecture. Annual Review of Biomedical298Data Science 1, 29-51 (2018).

299	2.	Y. Wang et al., Clonal evolution in breast cancer revealed by single nucleus genome
300		sequencing. <i>Natur</i> e 512 , 155-160 (2014).
301	3.	M. A. Lodato et al., Aging and neurodegeneration are associated with increased
302		mutations in single human neurons. Science 359 , 555-559 (2018).
303	4.	E. Shapiro, T. Biezuner, S. Linnarsson, Single-cell sequencing-based technologies will
304		revolutionize whole-organism science. Nature reviews. Genetics 14, 618-630 (2013).
305	5.	L. S. Ludwig et al., Lineage Tracing in Humans Enabled by Mitochondrial Mutations and
306		Single-Cell Genomics. <i>Cell</i> 176 , 1325-1339 e1322 (2019).
307	6.	B. Spanjaard et al., Simultaneous lineage tracing and cell-type identification using
308		CRISPR-Cas9-induced genetic scars. Nature biotechnology 36, 469-473 (2018).
309	7.	M. M. Chan et al., Molecular recording of mammalian embryogenesis. Nature 570, 77-82
310		(2019).
311	8.	B. Raj et al., Simultaneous single-cell profiling of lineages and cell types in the
312		vertebrate brain. Nature biotechnology 36, 442-450 (2018).
313	9.	L. Kester, A. van Oudenaarden, Single-Cell Transcriptomics Meets Lineage Tracing. Cell
314		stem cell 23 , 166-179 (2018).
315	10.	E. P. Mimitou et al., Multiplexed detection of proteins, transcriptomes, clonotypes and
316		CRISPR perturbations in single cells. <i>Nature methods</i> 16 , 409-412 (2019).
317	11.	I. C. Macaulay, C. P. Ponting, T. Voet, Single-Cell Multiomics: Multiple Measurements
318		from Single Cells. Trends in genetics : TIG 33 , 155-168 (2017).
319	12.	J. Packer, C. Trapnell, Single-Cell Multi-omics: An Engine for New Quantitative Models
320	12.	of Gene Regulation. <i>Trends in genetics : TIG</i> 34 , 653-665 (2018).
321	13.	C. Trapnell, Defining cell types and states with single-cell genomics. Genome research
322	10.	25 , 1491-1498 (2015).
323	14.	X. Qiu <i>et al.</i> , Reversed graph embedding resolves complex single-cell developmental
324	17.	trajectories. <i>bioRxiv</i> , (2017).
325	15.	S. Codeluppi <i>et al.</i> , Spatial organization of the somatosensory cortex revealed by cyclic
326	15.	smFISH. <i>bioRxiv</i> , (2018).
327	16.	J. Y. Kishi <i>et al.</i> , SABER enables highly multiplexed and amplified detection of DNA and
328	10.	RNA in cells and tissues. <i>bioRxiv</i> , (2018).
329	17.	G. Gut, M. D. Herrmann, L. Pelkmans, Multiplexed protein maps link subcellular
330	17.	organization to cellular states. Science 361 , (2018).
331	18.	C. L. Eng <i>et al.</i> , Transcriptome-scale super-resolved imaging in tissues by RNA
332	10.	
	19.	seqFISH. <i>Nature</i> 568 , 235-239 (2019).
333	19.	J. H. Lee <i>et al.</i> , Highly multiplexed subcellular RNA sequencing in situ. <i>Science</i> 343 , 1260, 1262 (2014)
334	20	1360-1363 (2014).
335	20.	K. H. Chen, A. N. Boettiger, J. R. Moffitt, S. Wang, X. Zhuang, RNA imaging. Spatially
336	04	resolved, highly multiplexed RNA profiling in single cells. <i>Science</i> 348 , aaa6090 (2015).
337	21.	S. Chevrier <i>et al.</i> , An Immune Atlas of Clear Cell Renal Cell Carcinoma. <i>Cell</i> 169 , 736-
338	00	749 e718 (2017).
339	22.	E. Lein, L. E. Borm, S. Linnarsson, The promise of spatial transcriptomics for
340	00	neuroscience in the era of molecular cell typing. Science 358 , 64-69 (2017).
341	23.	J. A. Weinstein, A. Regev, F. Zhang, DNA Microscopy: Optics-free Spatio-genetic
342	~ (Imaging by a Stand-Alone Chemical Reaction. <i>Cell</i> 178 , 229-241 e216 (2019).
343	24.	E. Klingler <i>et al.</i> , Single-cell molecular connectomics of intracortically-projecting neurons.
344	~-	bioRxiv, 378760 (2018).
345	25.	J. Cao et al., Comprehensive single-cell transcriptional profiling of a multicellular
346	~~	organism. Science 357 , 661-667 (2017).
347	26.	C. T. Fincher, O. Wurtzel, T. de Hoog, K. M. Kravarik, P. W. Reddien, Cell type
348		transcriptome atlas for the planarian Schmidtea mediterranea. Science 360 , (2018).
349	27.	X. Han et al., Mapping the Mouse Cell Atlas by Microwell-Seq. Cell 173, 1307 (2018).

350 28. K. Shekhar et al., Comprehensive Classification of Retinal Bipolar Neurons by Single-351 Cell Transcriptomics. Cell 166, 1308-1323 e1330 (2016). S. G. Rodrigues et al., Slide-seq: A scalable technology for measuring genome-wide 352 29. 353 expression at high spatial resolution. Science 363, 1463-1467 (2019). 30. 354 K. Bahar Halpern et al., Single-cell spatial reconstruction reveals global division of labour 355 in the mammalian liver. Nature 542, 352-356 (2017). 356 31. A. E. Moor et al., Spatial reconstruction of single enterocytes uncovers broad zonation 357 along the intestinal villus axis. bioRxiv, (2018). A. Regev et al., The Human Cell Atlas. eLife 6, (2017). 358 32. 359 D. M. Taylor et al., The Pediatric Cell Atlas: Defining the Growth Phase of Human 33. 360 Development at Single-Cell Resolution. Developmental cell 49, 10-29 (2019). 361 34. A. C. Villani et al., Single-cell RNA-seq reveals new types of human blood dendritic cells, 362 monocytes, and progenitors. Science 356, (2017). L. W. Plasschaert et al., A single-cell atlas of the airway epithelium reveals the CFTR-363 35. 364 rich pulmonary ionocyte. Nature 560, 377-381 (2018). 365 36. D. T. Montoro et al., A revised airway epithelial hierarchy includes CFTR-expressing 366 ionocytes. Nature 560, 319-324 (2018). 367 37. A. Zeisel et al., Brain structure. Cell types in the mouse cortex and hippocampus 368 revealed by single-cell RNA-seq. Science 347, 1138-1142 (2015). 369 38. B. B. Lake et al., Neuronal subtypes and diversity revealed by single-nucleus RNA 370 sequencing of the human brain. Science 352, 1586-1590 (2016). 371 39. A. Butler, P. Hoffman, P. Smibert, E. Papalexi, R. Satija, Integrating single-cell 372 transcriptomic data across different conditions, technologies, and species. Nature 373 biotechnology 36, 411-420 (2018). L. Haghverdi, A. T. L. Lun, M. D. Morgan, J. C. Marioni, Batch effects in single-cell RNA-374 40. 375 sequencing data are corrected by matching mutual nearest neighbors. Nature biotechnology 36, 421-427 (2018). 376 377 41. D. Calderon et al., Inferring Relevant Cell Types for Complex Traits by Using Single-Cell 378 Gene Expression, American journal of human genetics 101, 686-699 (2017). 379 42. H. Wu et al., Comparative Analysis and Refinement of Human PSC-Derived Kidney 380 Organoid Differentiation with Single-Cell Transcriptomics. Cell stem cell 23, 869-881 381 e868 (2018). 382 43. J. G. Camp et al., Human cerebral organoids recapitulate gene expression programs of 383 fetal neocortex development. Proceedings of the National Academy of Sciences of the 384 United States of America 112, 15672-15677 (2015). 385 44. A. S. Cuomo et al., Single-cell RNA-sequencing of differentiating iPS cells reveals 386 dynamic genetic effects on gene expression. bioRxiv, 630996 (2019). 387 H. M. Kang et al., Multiplexed droplet single-cell RNA-sequencing using natural genetic 45. 388 variation. Nature biotechnology, (2017). 389 46. G. T. Consortium et al., Genetic effects on gene expression across human tissues. 390 Nature 550, 204-213 (2017). 391 47. S. Maniatis et al., Spatiotemporal dynamics of molecular pathology in amyotrophic 392 lateral sclerosis. Science 364, 89-93 (2019). 393 48. H. Keren-Shaul et al., A Unique Microglia Type Associated with Restricting Development 394 of Alzheimer's Disease. Cell 169, 1276-1290 e1217 (2017). 395 49. D. Kuo et al., HBEGF(+) macrophages in rheumatoid arthritis induce fibroblast 396 invasiveness. Sci Transl Med 11, (2019). 397 A. Segerstolpe et al., Single-Cell Transcriptome Profiling of Human Pancreatic Islets in 50. 398 Health and Type 2 Diabetes. Cell metabolism, (2016). 399 51. C. S. Smillie et al., Intra- and Inter-cellular Rewiring of the Human Colon during 400 Ulcerative Colitis. Cell 178, 714-730 e722 (2019).

401 52. I. Tirosh, M. L. Suvà, Deciphering Human Tumor Biology by Single-Cell Expression 402 Profiling. Annual Review of Cancer Biology 3, 151-166 (2019). 403 53. T. M. Gierahn et al., Seq-Well: portable, low-cost RNA sequencing of single cells at high 404 throughput. Nature methods 14, 395-398 (2017). 405 S. M. Prakadan, A. K. Shalek, D. A. Weitz, Scaling by shrinking: empowering single-cell 54. 406 'omics' with microfluidic devices. Nature reviews. Genetics 18, 345-361 (2017). 407 55. H. Keren-Shaul et al., MARS-seq2.0: an experimental and analytical pipeline for indexed 408 sorting combined with single-cell RNA sequencing. Nature protocols 14, 1841-1862 409 (2019). 410 56. C. S. McGinnis et al., MULTI-seq: sample multiplexing for single-cell RNA sequencing 411 using lipid-tagged indices. Nature methods 16, 619-626 (2019). 412 57. M. Stoeckius et al., Simultaneous epitope and transcriptome measurement in single 413 cells. Nature methods 14, 865-868 (2017). 414 B. Clearv, L. Cong, A. Cheung, E. S. Lander, A. Regev, Efficient Generation of 58. 415 Transcriptomic Profiles by Random Composite Measurements. Cell 171, 1424-1436 416 e1418 (2017). 417 59. J. Park et al., Single-cell transcriptomics of the mouse kidney reveals potential cellular 418 targets of kidney disease. Science 360, 758-763 (2018). 419 Y. R. Peng et al., Molecular Classification and Comparative Taxonomics of Foveal and 60. 420 Peripheral Cells in Primate Retina. Cell 176, 1222-1237 e1222 (2019). 421 61. L. A. Williams, B. N. Davis-Dusenbery, K. C. Eggan, SnapShot: directed differentiation of 422 pluripotent stem cells. Cell 149, 1174-1174 e1171 (2012). 423 62. Y. Sasai, Cytosystems dynamics in self-organization of tissue architecture. Nature 493, 424 318-326 (2013). 425 63. H. Clevers, Modeling Development and Disease with Organoids. Cell 165, 1586-1597 426 (2016).427 64. M. A. Lancaster et al., Guided self-organization and cortical plate formation in human brain organoids. Nature biotechnology 35, 659-666 (2017). 428 429 S. Velasco et al., Individual brain organoids reproducibly form cell diversity of the human 65. 430 cerebral cortex. Nature 570, 523-527 (2019). 431 66. T. Takebe, J. M. Wells, Organoids by design. Science 364, 956-959 (2019). 432 67. J. G. Camp, D. Wollny, B. Treutlein, Single-cell genomics to guide human stem cell and 433 tissue engineering. Nature methods 15, 661-667 (2018). 434 68. J. Klaus et al., Altered neuronal migratory trajectories in human cerebral organoids 435 derived from individuals with neuronal heterotopia. Nat Med 25, 561-568 (2019). 436 69. A. M. Pasca et al., Human 3D cellular model of hypoxic brain injury of prematurity. Nat 437 Med 25, 784-791 (2019). 438 70. J. G. Doench, Am I ready for CRISPR? A user's guide to genetic screens. Nature 439 reviews. Genetics 19, 67-80 (2018). 440 71. L. Cong et al., Multiplex genome engineering using CRISPR/Cas systems. Science 339, 441 819-823 (2013). 442 72. P. Mali et al., RNA-guided human genome engineering via Cas9. Science 339, 823-826 443 (2013). 444 73. M. Jinek et al., A programmable dual-RNA-guided DNA endonuclease in adaptive 445 bacterial immunity. Science 337, 816-821 (2012). 446 74. O. Shalem et al., Genome-scale CRISPR-Cas9 knockout screening in human cells. 447 Science 343, 84-87 (2014). 448 75. T. Wang, J. J. Wei, D. M. Sabatini, E. S. Lander, Genetic screens in human cells using 449 the CRISPR-Cas9 system. Science 343, 80-84 (2014). 450 76. R. J. Ihry et al., Genome-Scale CRISPR Screens Identify Human Pluripotency-Specific 451 Genes. Cell reports 27, 616-630 e616 (2019).

- 452 77. L. A. Gilbert *et al.*, Genome-Scale CRISPR-Mediated Control of Gene Repression and
 453 Activation. *Cell* **159**, 647-661 (2014).
- 454 78. X. S. Liu *et al.*, Editing DNA Methylation in the Mammalian Genome. *Cell* **167**, 233-247
 455 e217 (2016).
- 456 79. I. B. Hilton *et al.*, Epigenome editing by a CRISPR-Cas9-based acetyltransferase
 457 activates genes from promoters and enhancers. *Nature biotechnology* 33, 510-517
 458 (2015).
- 80. N. M. Gaudelli *et al.*, Programmable base editing of A*T to G*C in genomic DNA without
 DNA cleavage. *Nature* 551, 464-471 (2017).
- 81. S. Konermann *et al.*, Transcriptome Engineering with RNA-Targeting Type VI-D CRISPR
 Effectors. *Cell* **173**, 665-676 e614 (2018).
- 46382.A. Pickar-Oliver, C. A. Gersbach, The next generation of CRISPR-Cas technologies and464applications. Nat Rev Mol Cell Biol 20, 490-507 (2019).
- 465 83. S. Konermann *et al.*, Genome-scale transcriptional activation by an engineered
 466 CRISPR-Cas9 complex. *Nature* 517, 583-588 (2015).
- 467 84. L. A. Gilbert *et al.*, CRISPR-mediated modular RNA-guided regulation of transcription in eukaryotes. *Cell* **154**, 442-451 (2013).
- 46985.S. Konermann *et al.*, Optical control of mammalian endogenous transcription and
epigenetic states. *Nature* **500**, 472-476 (2013).
- 471 86. Y. Chen *et al.*, Engineering Human Stem Cell Lines with Inducible Gene Knockout using
 472 CRISPR/Cas9. *Cell stem cell* **17**, 233-244 (2015).
- 47387.F. Gonzalez *et al.*, An iCRISPR platform for rapid, multiplexable, and inducible genome474editing in human pluripotent stem cells. *Cell stem cell* **15**, 215-226 (2014).
- 47588.A. Dixit *et al.*, Perturb-Seq: Dissecting Molecular Circuits with Scalable Single-Cell RNA476Profiling of Pooled Genetic Screens. *Cell* **167**, 1853-1866 e1817 (2016).
- 477 89. B. Adamson *et al.*, A Multiplexed Single-Cell CRISPR Screening Platform Enables
 478 Systematic Dissection of the Unfolded Protein Response. *Cell* 167, 1867-1882 e1821
 479 (2016).
- 48090.D. A. Jaitin *et al.*, Dissecting Immune Circuits by Linking CRISPR-Pooled Screens with481Single-Cell RNA-Seq. Cell 167, 1883-1896 e1815 (2016).
- 482 91. P. Datlinger *et al.*, Pooled CRISPR screening with single-cell transcriptome readout.
 483 *Nature methods* 14, 297-301 (2017).
- 484 92. A. Rodriguez-Meira *et al.*, Unravelling Intratumoral Heterogeneity through High485 Sensitivity Single-Cell Mutational Analysis and Parallel RNA Sequencing. *Molecular cell*486 73, 1292-1305 e1298 (2019).
- 487 93. F. Schmidt, M. Y. Cherepkova, R. J. Platt, Transcriptional recording by CRISPR spacer
 488 acquisition from RNA. *Nature* 562, 380-385 (2018).
- 489 94. D. Feldman et al., Pooled optical screens in human cells. bioRxiv, 383943 (2018).
- 490 95. M. Belle *et al.*, Tridimensional Visualization and Analysis of Early Human Development.
 491 *Cell* 169, 161-173 e112 (2017).
- 492 96. K. McDole *et al.*, In Toto Imaging and Reconstruction of Post-Implantation Mouse
 493 Development at the Single-Cell Level. *Cell* **175**, 859-876 e833 (2018).
- 49497.C. Pan *et al.*, Shrinkage-mediated imaging of entire organs and organisms using495uDISCO. Nature methods 13, 859-867 (2016).
- 49698.A. T. Wassie, Y. Zhao, E. S. Boyden, Expansion microscopy: principles and uses in
biological research. *Nature methods* **16**, 33-41 (2019).
- 498 99. O. Legetth *et al.*, CellexalVR: A virtual reality platform for the visualisation and analysis
 499 of single-cell gene expression data. *bioRxiv*, 329102 (2019).
- 500100.H. Kilpinen *et al.*, Common genetic variation drives molecular heterogeneity in human501iPSCs. Nature **546**, 370-375 (2017).

- 502 101. B. Roberts *et al.*, Fluorescent Gene Tagging of Transcriptionally Silent Genes in hiPSCs.
 503 Stem Cell Reports **12**, 1145-1158 (2019).
- A. E. Chen *et al.*, Optimal timing of inner cell mass isolation increases the efficiency of human embryonic stem cell derivation and allows generation of sibling cell lines. *Cell stem cell* 4, 103-106 (2009).

508 ACKNOWLEDGEMENTS

- 509 We thank Treutlein and Camp labs, and B. Roska for helpful discussions. **Funding:** This work
- 510 was supported by the Chan Zuckerberg Initiative (BT/JGC), European Research Council
- 511 (ANTHROPOID, JGC; ORGANOMICS; BT), Swiss National Science Foundation (JGC, RJP),
- 512 ETH domain Personalized Health and Related Technologies (RJP), Brain and Behavior
- 513 Research Foundation (RJP), National Centre of Competence in Research Molecular Systems
- 514 Engineering (RJP, BT), ETH Zürich (RJP, BT), and Institute of Molecular and Clinical
- 515 Ophthalmology Basel (JGC). Author Contributions: All authors contributed to researching and
- 516 writing the study. **Competing interests:** The authors have no competing interests. **Data and**
- 517 materials availability: There is no new data generated in this manuscript.

518

519